Coronavirus-19, Covid-19, pandemic

Naltrexone a potential therapeutic candidate for COVID-19 (Abstract)

J Biomol Struct Dyn
15 Sept 2020
https://pubmed.ncbi.nlm.nih.gov/32930058/

Survey-reported medication changes among older adults during the SARS-CoV-2 (COVID-19) pandemic (Abstract)

Res Social Adm Pharm
12 Nov 2020
https://pubmed.ncbi.nlm.nih.gov/33221267/

Dickson Chemist developed a new formulation of LDN which will hopefully improve the outcomes for patients. This new formulation is a more concentrated liquid in the form of drops which are administered under the tongue and absorbed directly from the mucosal lining of the mouth. This sublingual route produces a more rapid absorption bypassing the liver and digestive tract. There are several potential advantages to this, the drug may be more effective and will not be affected by the presence of food stuffs or the hostile environment of the gut.